HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

NCT04252417 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Due to other Phase 3 trial failure to meet primary endpoint

Conditions

Healthy Volunteers
Hepatic Impairment of Moderate Child Pugh Category

Interventions

DRUG: MD1003

Sponsor

MedDay Pharmaceuticals SA

Collaborators

[object Object]